Neurogene Inc. (NGNE) Stock Ticker
NGNE right now
Market factors today
Unlock the full NGNE picture
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE stock facts
| Ticker symbol | NGNE |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $447.4M |
| CEO | Rachel L. McMinn |
| Employees | 131 |
| Headquarters | New York City, NY, US |
| IPO date | 2014-03-07 |
| Website | www.neurogene.com |
What you can see for NGNE on Tickr
Live NGNE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NGNE report.
Rankings
FAQ
What is the ticker symbol for Neurogene Inc.?
The ticker symbol for Neurogene Inc. is NGNE, listed on the NASDAQ Global Market.
What is NGNE?
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype…